Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 25 · below the Ichimoku cloud · RSI 36 · MACD below its signal · 2% above its 52-week low
| 2.62 | 52-week high | +164.24% |
| 1.43 | Previous month high | +44.95% |
| 1.13 | R3 (classic) | +13.87% |
| 1.10 | Previous month low | +11.11% |
| 1.10 | R2 (classic) | +10.98% |
| 1.09 | Previous week high | +10.10% |
| 1.07 | Previous day high | +8.08% |
| 1.04 | R1 (classic) | +5.49% |
| 1.02 | Pivot | +2.59% |
| 0.9900 | Price now | |
| 0.9870 | Previous day low | −0.30% |
| 0.9870 | Previous week low | −0.30% |
| 0.9740 | 52-week low | −1.62% |
| 0.9613 | S1 (classic) | −2.90% |
| 0.9327 | S2 (classic) | −5.79% |
| 0.8783 | S3 (classic) | −11.28% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $788.3K | 0.00% | 563.06K | +70% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CHRS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 52.1 | -22.7 | 1.2 | 5.0 | -10.4 | -11.9 | 0.7 | -4.3 | -10.4 | -18.2 | −30.3% | ||
| 2025 | -14.5 | -5.9 | -27.3 | 27.6 | -24.4 | -6.2 | 28.6 | 23.4 | 41.4 | 2.4 | -19.0 | 4.4 | +2.9% |
| 2024 | -35.4 | 6.0 | 4.8 | -18.0 | -7.1 | -4.9 | -11.0 | -9.7 | -25.2 | -28.4 | 63.8 | 13.1 | −58.6% |
| 2023 | 7.1 | -20.2 | 1.0 | 5.7 | -43.4 | 4.4 | 12.9 | 10.6 | -29.8 | -10.4 | -36.4 | 56.3 | −58.0% |
| 2022 | -22.6 | -4.6 | 9.5 | -30.0 | -18.8 | -1.4 | 17.0 | 32.0 | -14.0 | -9.5 | -21.1 | 15.5 | −50.4% |
| 2021 | 8.2 | -13.6 | -10.0 | 1.3 | -11.1 | 5.1 | -5.6 | 22.5 | 0.6 | 4.1 | 11.0 | -14.1 | −8.2% |
| 2020 | 0.2 | 7.3 | -16.2 | 2.3 | 12.3 | -4.2 | -1.5 | 7.8 | -3.3 | -9.1 | 10.7 | -5.9 | −3.5% |
| 2019 | 48.7 | 6.5 | -4.9 | 16.7 | 18.7 | 16.9 | -23.9 | 31.9 | -8.7 | -14.3 | 3.6 | 0.1 | +99.0% |
| 2018 | 14.8 | -2.0 | 11.6 | 9.5 | 28.9 | -10.3 | 36.1 | 5.8 | -18.1 | -29.2 | -5.4 | -18.2 | +2.8% |
| 2017 | -0.9 | -15.4 | -10.4 | -9.2 | 2.9 | -27.3 | -8.7 | 10.3 | -7.6 | -15.7 | -20.4 | -1.7 | −68.7% |
| 2016 | -42.2 | 7.0 | 49.6 | -11.3 | -1.0 | -9.4 | 50.3 | 17.3 | -10.0 | 2.1 | -1.6 | 4.6 | +22.6% |
| 2015 | 37.5 | 40.8 | -3.2 | -28.8 | 12.9 | 17.6 | 21.4 | -21.3 | -27.4 | 39.0 | 9.0 | -24.4 | +40.7% |
| 2014 | 18.9 | +18.9% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Satvat Ali JDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 4, 2026 | Newcomer Lee NisleyDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 4, 2026 | Newton Charles W.Director | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 4, 2026 | O'Donnell-Tormey Jill Ph.D.Director | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 4, 2026 | Ryan Michael LeeDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 4, 2026 | Wahlstrom MatsDirector | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 4, 2026 | Karachun Rita A.Director | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jan 22, 2026 | Lanfear Dennis MChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 375K | — |
| Jan 21, 2026 | Mcmichael Bryan JChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 112.5K | — |
| May 22, 2025 | Wahlstrom MatsDirector | Sale at price 0.74 per share. | 100K | $73.88K |
Buy / hold / sell counts
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.